AMGT 0240
Alternative Names: AMGT-0240Latest Information Update: 04 Jun 2025
At a glance
- Originator Amalgent Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Inflammation
Most Recent Events
- 30 May 2025 Early research in Inflammation in USA (PO) prior to May 2025 (Amalgent Therapeutics pipeline; May 2025)